
News|Articles|May 1, 2002
Cardiac events: Losartan beats beta blocker in patients with diabetes,HTN, & LVH
Therapy starting with the angiotensin receptor blocker (ARB) losartansignificantly reduced the risk of cardiovascular outcomes and new-onsetdiabetes compared with a beta blocker in older high-risk hypertensive patients,said Björn Dahlöf, MD. The improved outcomes with losartan occurredeven after adjusting for small differences in blood pressure reduction betweenthe two study drugs.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
2
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
3
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
4
DCIS Redefined: Circulating Tumor Cells Prove Early Dissemination and Challenge the 'Preinvasive' Label
5



















































